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High levels of urokinase receptor (uPAR) in tissue and serum of patients with chondrosarcoma correlate with poor prognosis.
First, we analyzed the uPAR levels in tissues and plasma of ﬁve patients aﬀected by chondrosarcoma. Interestingly, very high
levels of uPAR and its soluble forms (SuPAR) were found on tumor cell surfaces and plasma, respectively, of two patients with
lung metastases. Therefore, to investigate the role of SuPAR in chondrosaromas, we generated a primary cell culture from a
chondrosarcoma tissue overexpressing uPAR on cell surfaces. We found that chondrosarcoma-like primary culture cells release
a large amount of SuPAR in the medium. In vitro, SuPAR elicits chondrosarcoma cell migration likely through its uPAR88−92
sequence, since the DII88−183 or DIIDIIR88−284 uPAR domains retain motogen eﬀect whereas DI1−87 or DIII184−284 domains, both
lacking the uPAR88−92 sequence, are ineﬀective. Chondrosarcoma cells cross matrigel in response to SuPAR, and their invasion
capability is abrogated by RERF peptide which inhibits uPAR88−92 signalling. These ﬁndings assign a role to uPAR in mobilizing
chondrosarcoma cells and suggest that RERF peptide may be regarded as a prototype to generate new therapeutics for the
chondrosarcoma treatment.
1.Introduction
Chondrosarcomas are a heterogeneous group of neoplasms
having in common the production of cartilage matrix
by the tumor cells [1]. Chondrosarcoma accounts for
approximately 20% of bone sarcomas with a peak incidence
in the ﬁfth to seventh decade of life. Because there are
no eﬀective treatments for patients with unresectable or
metastatic disease, there is a pressing need to develop new
targeted approaches [2].
Chondrosarcomas can progress from low grade to high
grade, which is reﬂected by increased cellularity, nuclear
atypia, mucomyxoid matrix changes, and increased vascu-
larization [3, 4]. Low-grade chondrosarcomas are locally
aggressive but rarely metastasize [5]. By contrast, high-grade
chondrosarcomas often metastasize and are lethal in most
patients [3]. The molecular mechanisms involved in the
progression to high-grade chondrosarcoma are beginning to
be unravelled [1]. Furthermore, processes such as tumor cell
a t t a c h m e n t ,m i g r a t i o n ,a n di n v a s i o n ,w h i c ha r ek n o w nt ob e
fundamental in carcinoma, have not been similarly explored
in chondrosarcoma.
Proteolytic degradation of the extracellular matrix con-
stituents and modiﬁcation of cell adhesion properties are
required for tumor invasion and metastasis. The urokinase
plasminogen activator (uPA) system have an important
role in tumorigenesis, extracellular matrix degradation,
and migration and invasion of tumor cells [6–10]. Upon
binding to uPA, the cell-surface urokinase receptor (uPAR)
elicits a variety of cell responses, including cell migration2 Sarcoma
and invasion [11]. Many malignant cultured cell lines and
human neoplasmshavebeencharacterized bytheirincreased
uPAR expression [12, 13], thus suggesting that the inhibition
of uPAR activity could be a promising strategy to prevent
cancer invasion and metastasis.
uPAR is a glycosylated glycosylphosphatidylinositol-
anchored protein [14] formed by three domains DI, DII,and
DIII connected by short linker regions [15]. The Ser88-Arg-
Ser-Arg-Tyr92 (uPAR88–92) linker region between DI and DII
domains is a protease sensitive region which retains chemo-
tactic activity, even in the form of an isolated SRSRY peptide
[16, 17]. The ﬂexibility of this region enables its interaction
with a wide variety of ligands [18]. uPAR engagement
with uPA favours the exposure of the uPAR88–92 sequence
which, in turn, promotes cytoskeletal rearrangements and
directional cell migration by binding to the G-protein-
coupled formyl-peptide receptors (FPRs) [16, 17, 19]. By
a drug-design approach based on the conformational anal-
ysis of the uPAR88–92 sequence, we have recently developed
a family of peptides which revealed to be uPAR antagonists
in virtue of their ability to prevent uPAR/FPR interaction.
Among these, we found that RERF peptide potently inhibits
in vitro and in vivo cell migration and invasion of highly
invasive human ﬁbrosarcoma HT1080 cells [20].
In tumor tissues, shedding and/or enzymatic cleavage of
uPAR generate truncated forms of uPAR (SuPAR), which are
secreted in the extracellular milieu [21–24]. Soluble forms
of uPAR have been identiﬁed, in vitro, in conditioned cell
culture medium and, in vivo, in serum and urine of patients
aﬀected by several type of solid tumors, including sarcomas
and chondrosarcamas, and have been signiﬁcantly associated
to a bad prognosis [21–25]. In particular, codetection of a
high expression level of uPA, uPAR, and PAI-1 in tumour
tissue and of SuPAR in serum of patients aﬀected by soft-
tissue sarcoma has been reported to signiﬁcantly correlate
with a shortened overall survival [25]. To gain some insight
on the role of soluble forms of uPAR in determining an
aggressive phenotype of chondrosarcoma, we have analysed
the eﬀects of SuPAR on a primary cell culture derived from
an uPAR expressing chondrosarcoma case.
2.Materialsand Methods
2.1. Patients, Tissue and Plasma Collection. Six patients with
chondrosarcoma were studied. Surgical removed tumors
were routinely processed for the histopathological diagnosis
performed according to the WHO classiﬁcation [26]. A
representative sample from each tumor excision was imme-
d i a t e l yf r o z e ni nl i q u i dn i t r o g e na n ds t o r e da t−80◦Cu n t i l
used for immunocytochemistry. A sample from the tumor
excision of patient no. 6 was immediately processed for
preparation of a primary cell culture. Plasma samples were
obtained just before surgery and were stored at −80◦Cu n t i l
assayed.
2.2. Immunohistochemistry. Frozen sections, corresponding
to the largest cross-sectional area of the tumor, were cut,
placed on glass slides and subjected to immunostaining
with the streptavidin-biotin-peroxidase method, as pre-
viously described [27]. Brieﬂy, sections were ﬁxed with
2.5% formaldehyde in phosphate buﬀered saline (PBS)
and incubated overnight at 4◦C with diluents (negative
control), or 2μg/mL R4 anti-uPAR monoclonal antibody
(mAb), kindly provided by G. Hoyer-Hansen (Finsen Insti-
tute, Copenhagen, Denmark). After several washes in PBS,
1:200 diluted biotinylated goat anti-mouse immunoglob-
ulins were applied to sections at 23◦C for 60min. There-
after, sections were incubated with streptavidin-biotinylated
horseradish peroxidase complex for additional 30min
and the peroxidase-dependent staining was developed by
diaminobenzidine. Slides were counterstained with Mayer’s
haematoxylin.
2.3. Primary Cell Culture. A representative sample from
the tumor excision (∼1cm × 1cm) from patient no. 6
was immediately minced by scalpel under sterile conditions
and incubated with 1.0mg/mL collagenase XI (Sigma) for
3hat37 ◦C under gentle agitation, as previously described
[28]. Cells, recovered by centrifugation at 1500rpm, were
cultured in 6-well multidish plates in Dulbecco Modiﬁed
Essential Medium (DMEM) with the addition of 10% foetal
bovine serum (FBS), 100IU/mL penicillin and 50μg/mL
streptomycin. Isolated cell clusters were further ampliﬁed
in growth medium until an adherent, homogeneous cell
population was obtained.
2.4. Cell Lines and Conditioned Media. Mouse ﬁbroblast
LB6, LB6 cells stably transfected with cDNA encoding
human SuPAR (LB6/hSuPAR) [12], and human ﬁbrosar-
coma HT1080 cell line were grown in DMEM supplemented
with 10%FBS, 100IU/mL penicillin and 50μg/mL strepto-
mycin. To prepare conditioned media, LB6, LB6/hSuPAR,
or chondrosarcoma cells were grown to 80% conﬂuence on
10cmØplates.Growth mediumwasremovedand cells,after
extensive washing with PBS, were incubated in serum-free
medium. After 18h, the medium was recovered, cleared by
centrifugation, and analysed for the SuPAR content applying
a commercially available enzyme-linked immunosorbent
assay kit (ELISA) purchased by R&D System, as previously
described [12]. Antigen concentrations were expressed as ng
analyte per μgp r o t e i n s .
2.5. Immunoﬂuorescence. Chondrosarcoma cells, plated on
glass slides (30%–40% conﬂuence), were ﬁxed and perme-
abilized with 2.5% formaldeyde-0.2% Triton X-100 in PBS
for 10min at 4◦C, then incubated overnight at 4◦Cw i t h
5μg/mL anti-vimentin (Dako), anti-cytokeratin (Zymed
Laboratories Inc.) or 2μg/mL R4 anti-uPAR mAbs. A
subset of experiments was performed on ﬁxed with 2.5%
formaldeyde, nonpermeabilized cells. Immunoﬂuorescence
wascarriedoutbyincubatingslideswith1:100dilutedAlexa
488-conjugated F(ab’)2 fragment of rabbit anti-mouse IgG
(Molecular Probes) for 1h at 22◦C. After nuclear staining
with 4 6-diamidino-2-phenylindole dye (DAPI), cells were
analysed by a ﬂuorescence inverted microscope connected to
a videocamera (Carl Zeiss), as described [20].Sarcoma 3
2.6. Flow Cytometry. Cells were detached using 200mg/L
EDTA, 500mg/L trypsin (Cambrex). Nonspeciﬁc binding
sites,possibly duetoany Fcreceptor,were blockedbynormal
rat serum. Cells(0.5 × 106 cells/sample) were incubated with
1:40 normal rat serum added to PBS (CTL) or 2μg/mL
R4 anti-uPAR mAb for 30min at 4◦C. After extensive
washing with PBS, cells were incubated with Alexa 488-
conjugated F(ab’)2 fragment of rabbit anti-mouse IgG and
ﬁnally resuspended in 0.6mL PBS. Samples were analysed
by ﬂow cytometry using a FACS Vantage cell sorter (Becton
& Dickinson). All data were analysed using CellQuest
software.
2.7. Immunoprecipitation. Conditioned medium of LB6,
LB6/hSuPAR or chondrosarcoma cells (500μL/sample) were
precleared with 10μL Protein G-Sepharose (Ge-Healthcare)
for 1hr at 4◦C, immunoprecipitated with 100μL rabbit
399 anti-uPAR conjugated to sepharose beads (0.5mg IgG
per mL of beads)d i l u t e d1 : 1f o r1 8 ha t4 ◦C. Beads were
washedandthenboiledinSDS-PAGEsamplebuﬀer.Proteins
were separated by a 12.5% SDS-PAGE followed by Western
blotting with 2μg/mL R4 anti-uPAR mAb.
2.8. Cell Migration and Invasion Assays. Cell migration and
invasion assays were performed using Boyden chambers
and8μm poresize polyvinyl-pyrrolidone-free polycarbonate
ﬁlters (Nucleopore) as previously described [20, 27]. The
ability of primary cell culture to migrate or to cross matrigel
was assessed between the VI and the IX passage. For cell
invasion assays, ﬁlters were coated with 50μg/mL matrigel,
a reconstituted basement membrane (BD Biosciences). Cells
were preincubated with DMEM, 2μg/mL normal rabbit
serum (NRS), blocking 399 anti-uPAR Ab [29, 30], or
anti-uPAR84–95 Ab which speciﬁcally recognizes the uPAR
chemotactic Ser88-Arg-Ser-Arg-Tyr92 sequence [31]f o r1 h
at 37◦C, prior to seeding in the upper chamber at 3 × 104
cells/well. In a subset of experiments, cells were exposed
to 10nM RERF or ERFR peptides (Primm) which we
have previously reported to inhibit uPAR88–92-dependent
signalling without aﬀecting cell proliferation [20]. The
indicated chemoattractants were placed in the bottom well.
Recombinant uPAR domains (Calbiochem) were employed
at 10nM concentration. Cells were allowed to migrate or
invade matrigel at 37◦C in humidiﬁed air with 5% CO2
for 4h or 18h, respectively. At the end of the assay, cells
in the upper chamber and on the upper ﬁlter surface were
removed whereas cells on the lower ﬁlter surface were ﬁxed
with ethanol and stained with haematoxylin. The number
of migrating or invading cells was determined by count-
ing cells in 10 random ﬁelds/ﬁlter at 200x magniﬁcation.
HT1080 cells were employed as an internal control. Data
were calculated as a percentage of migrated or invading
cells in the absence of chemoattractant, considered as
100%.
2.9. Statistical Analysis. T h ed a t aw e r ea n a l y s e df o rs i g n i f -
icance using Student’s t-test. Diﬀerences were considered
statistically signiﬁcant at a level of P<. 05.
3.Resultsand Discussion
3.1.uPARExpression and SuPARRelease in Chondrosarcomas.
The age of the patients at diagnosis ranged from 34 to 72
years. Surgical removed tumors were routinely processed for
the histopathological diagnosis performed according to the
WHO classiﬁcation [26]. Table 1 reports the pathological
ﬁndings of 6 primary chondrosarcomas: 5 were primary
bone lesions including femur (3) and sternum (2) and 1
was extraskeletal lesion involving pelvis (Table 1). The main
clinical features at diagnosis are summarized in Table 2.
To investigate the molecular mechanisms underlying the
activity of uPAR in chondrosarcoma, we ﬁrst analysed the
uPAR expression on chondrosarcoma tissues by immuno-
histochemistry, using R4 anti-uPAR mAb. The intensity of
uPAR staining of tumor cells was graded as faint (grading
1), moderate (grading 2), or intense (grading 3) (Table 2).
Except for the benign/low grade lesion which did not show
any reactivity to R4 anti-uPAR mAb, all tumors, although
at a diﬀerent extent, exhibit a heterogeneous pattern of
staining, mainly localized on tumor plasma cell membranes
(Figure 1). Several tumor cells have been reported to shed
soluble forms of uPAR [21–25]. Therefore, we performed a
quantitativeanalysisoftheofSuPARcontentintheplasmaof
patients using a commercially Elisa Kit. As shown in Table 2,
an appreciable amount of SuPAR was detected in all the
plasma tested. Interestingly, patients with lung metastases
(#3and #4)exhibitedhigherlevelsofSuPAR(Table 2).These
data encouraged us to further analyze the role of SuPAR in
chondrosaroma invasiveness.
The patient no. 6 underwent a surgery for an extensive
sternal mass (Table 1). Preoperative workup showed bilateral
nodules suspicious for pulmonary metastases. Following
multidisciplinary consultation, it was decided to submit
the patient to complete sternal resection and pulmonary
metastasectomy. For the reconstruction of the anterior chest
walldefect,threecadavericcryopreservedribswereused.The
resected tumor measured 18 × 15 × 8cm. Histology of the
primary tumor yielded a diagnosis of grade 2, focally grade
3 chondrosarcoma, characterized by frank hypercellularity,
with elongated hyperchromatic and sometimes binucleated
nuclei (Figure 2(a)). The pulmonary lesions were conﬁrmed
to be pulmonary metastases from chondrosarcoma. The
patient was followed up to 8 months after primary surgery,
when multiple extraskeletal metastases were detected. At this
point, he received chemotherapy, but died soon after due to
chemotherapy-related complications.
3.2. Isolation and Characterization of Chondrosarcoma Cells.
As described in the methods, a representative sample from
the tumor excision was minced and subjected to enzymatic
digestion; cell suspension was recovered and cultured in
multidish plates until tothethird passage (Figure 2(b)).Sub-
cloning of the isolated cell clusters (Figure 2(c)) and seven
further passages resulted in an adherent, homogeneous cell
population mainly characterized by small chondrosarcoma-
like cells (Figure 2(d)), resembling, in shape and size, those
observedonhaematoxilin/eosin stained section (Figures3(a)
and 3(b)). Immunocytochemical analysis of cells grown on4 Sarcoma
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Figure 1: uPAR protein is expressed in chondrosarcoma tissues. Immunohistochemistry was performed on frozen sections with the
streptavidin-biotin-peroxidase method using 2μg/mL R4 anti-uPAR mAb. Sections were counterstained with haematoxylin. Original
magniﬁcations:x400.
Table 1: Histopathologicalﬁndings of enrolled chondrosarcoma patients.
Patients Age (yr) Gender Site Size (cm) Histologya Grade
14 2 F Right
femur 5.5 × 2 × 2.5 Low-grade chondrosarcoma
23 4 F P e l v i s 1 0 × 8 × 8 Mesenchymal chondrosarcoma G2
37 2 M Left
femur 21 × 12 × 12 Dediﬀerentiated chondrosarcoma G3
46 3 F Right
femur 13 × 9 × 28 Dediﬀerentiated chondrosarcoma G3
56 9 M S t e r n u m 1 0 × 7 × 5 Chondrosarcoma G2, focallyG3
65 8 M S t e r n u m 1 8 × 15 × 8 Chondrosarcoma G2, focallyG3
aHistopathological diagnosis was performed according to the WHO classiﬁcation.F, female;M, male.
Table 2: Clinicopathological parameters and uPAR levels in tumour tissues and in plasma of patients with chondrosarcoma.
Patients First clinical
evaluation Therapy Survival from
diagnosis (months)
uPAR
gradinga
SuPAR
(pg/mL)b
1 P Surgery 6 0 1094
2 P Surgery 87 1 1.508
3 P + Lung M Surgery 3 3 3.645
4P + L u n g M Neoadiuvant chemotherapy
and surgery 14 3 5.152
5 P Surgery 9 2 1.556
6 P + Lung M Surgery and chemotherapy 8 3 ND
P, primary tumor; M, metastasis; aImmunohistochemical staining of tumor frozen sections with R4 anti-uPAR mAb was graded as absent (grading 0), faint
(grading 1), moderate (grading 2), or intense (grading 3). bDetermination of plasmaticSuPAR content by Elisa,expressed as pg SuPAR/mL plasma.Sarcoma 5
(a) (b)
(c) (d)
Figure 2: Generation of a primary cell culture from a chondrosarcoma tissue. (a) Haematoxylin/eosin stained section of a human primary
grade 2, focallygrade 3 chondrosarcoma ofsternum (patient no.6). (b–d) A representative sample from the tumor excisionwas subjected to
enzymaticdigestion.Theisolatedcells,recovered by centrifugation at1500rpm,were cultured inDMEM 10%FBS until to thethird passage.
At this passage, cell population showed an evident cellular heterogeneity (b). Subcloning of the isolated cell clusters (c) and ampliﬁcation
for six further passages resulted in an adherent, homogeneous cell population characterized by small, chondrosarcoma-likecells (d). Images
were captured by an inverted microscope connected to a video camera. Original magniﬁcation:x200 (a and c), x400 (b and d).
glass slides revealed the total absence of epithelial (cytoker-
atin) cell marker whereas a strong staining was observed in
the 95% of cells exposed to anti-vimentin mAb (Figures 3(c)
and 3(d)).
3.3. Identiﬁcation of Membrane-Anchored uPAR on Chon-
drosarcoma Cells. First, uPAR expression was analysed in
chondrosarcoma cells by immunoﬂuorescence and cytoﬂu-
orimetry. Accordingly to immunohistochemical ﬁndings
(Figure 1), chondrosarcoma cells express high levels of uPAR
mainly localized on plasma cell membranes (Figure 4(a)). In
permeabilized cells, a discrete, intracytoplasmic amount of
uPAR was also found, thus indicating that chondrosarcoma
cells eﬀectively synthesize uPAR (Figure 4(b)). Interestingly,
ﬂow cytometry revealed that chondrosarcoma cells express
higher levels of uPAR as compared to HT1080 cells (25 and
23,9 mean ﬂuorescence intensity, resp., in the 98% of total
cells) (Figure 4(c)).
3.4. Chondrosarcoma Cells Shed Soluble Forms of uPAR into
theMedium. WeinvestigatedwhethersolubleformsofuPAR
are produced and released by chondrosarcoma cells in the
culture medium. To this purpose, we took advantage by
employing, as a negative and a positive controls, conditioned
medium of uPAR lacking wild-type LB6 and transfected
LB6/hSuPAR cells, respectively. We measured by Elisa the
amount of SuPAR antigen released in the conditioned
medium of LB6, LB6/hSuPAR and chondrosarcoma cells.
As expected, LB6/hSuPAR cells released a large amount of
SuPAR as compared to the wild-type LB6 cells [12]. In
keepingwith theexpression ofhigh levelsofuPARon plasma
cell membranes, chondrosarcoma cells released a very large
amount of SuPAR in the medium as compared to that
produced by LB6/hSuPAR cells (10.3ng/μga n d5 . 2n g / μgo f
proteins, resp.) (Figure 4(d)). To ascertain the occurrence
of cleaved forms of SuPAR in the conditioned medium of
chondrosarcoma cells, serum-free medium was subjected
to immunoprecipitation with rabbit 399 anti-uPAR Ab
which recognizes all soluble forms of SuPAR, followed by
Western blotting with R4 anti-uPAR mAb which recognizes
full-length DIIDIII and DIII cleaved forms of uPAR [24].
LB6 and LB6/hSuPAR conditioned media were employed
as negative and positive control, respectively. According to
Sidenius et al. [24], we found in the conditioned medium
of both chondrosarcoma and LB6/hSuPAR, but not LB6
cells, a fragment with an approximate 45kDa molecular
weight, comigrating with the puriﬁed full-length SuPAR
(Figure 4(d)). R4 anti-uPAR mAb speciﬁcally recognized
in the conditioned medium of LB6/hSuPAR but not LB6
cells an additional fragment having molecular weight of
about 35kDa, compatible with the cleavedDIIDIII fragment6 Sarcoma
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Figure 3: Immunophenotyping of chondrosarcoma cells. (a, b) haematoxilin/eosin stained chondrosarcoma cells resemble in shape and
size those of chondrosarcoma tissue section. (c, d) chondrosarcoma cells grown on glass slides to semiconﬂuence were stained with anti-
cytokeratin (CK) or anti-vimentin mAbs and with Alexa 488-conjugated F(ab’)2 fragment of rabbit anti-mouse IgG (green). Nuclei were
stained blue with DAPI. Original magniﬁcation:x400.
of SuPAR. As shown in Figure 4(e), a fragment with an
approximate 35kDa molecular weight, comigrating with the
DIIDIII fragment of SuPAR was found in the conditioned
medium of chondrosarcoma cells. Although we can not
assess whether other fragments of SuPAR do exist in the
chondrosarcoma cell medium, this ﬁndings indicate that
at least two fragments, both containing the chemotactic
sequence of uPAR, may inﬂuence cell behaviour.
3.5. SuPAR Promotes In Vitro Migration of Human Chon-
drosarcoma Cells. Soluble forms of uPAR, including the
DIIDIIIfragment, havebeenshowntostrongly chemoattract
a variety of cell types [16, 17, 20, 32]. We investigated
whetherchondrosarcoma cellsspeciﬁcally respond tosoluble
forms of uPAR. In these experiments, we took advantage
by employing the uPAR expressing human ﬁbrosarcoma
HT1080 cells as an internal control. Cell migration assays
werecarriedinBoydenchambersusingconditionedmediaof
wild-type LB6 or LB6/hSuPAR cells. We found that similarly
to HT1080, chondrosarcoma cells exhibited a strong ability
to migrate toward the LB6/hSuPAR conditioned medium,
reaching 363 ± 26% of the random cell migration (Table 3).
On the contrary, wild-type LB6 conditioned medium
did not exert any eﬀect, indicating that chondrosarcoma
cells speciﬁcally respond to SuPAR. Interestingly, 10nM
recombinant DII88–183 or DIIDIII88–284 uPAR domains as
well as full length DIDIIDIII1–284 triggered an appreciable
cell migration (215% ± 5, 221% ± 13, and 240% ± 10,
resp.) whereas recombinant DI1–87 or DIII184–284 uPAR
domains, both lacking the uPAR88–92 sequence, were
ineﬀective at 10nM (Table 3). These ﬁndings suggest that
SuPAR is able to mobilize chondrosarcoma cells through its
uPAR88–92 sequence. To further investigate the role of the
uPAR88–92 sequence in mobilizing chondrosarcoma cells, a
subset of experiments was performed in the presence of 399
anti-uPAR Ab or a polyclonal antibody which speciﬁcally
recognized the uPAR84–95 sequence [30, 31]. As shown in
Table 3, in the presence of 399 anti-uPAR or anti- uPAR84–95
Abs, both HT1080 and chondrosarcoma cells failed to
respond to the conditioned medium of LB6/hSuPAR cells or
to recombinant uPAR domains containing the chemotactic
sequence. The inhibition was speciﬁc, as the presence
of nonimmune serum did not abrogate cell motility. All
together, these results clearly indicate that soluble forms
of uPAR containing the uPAR88–92 sequence are able to
mobilize chondrosarcoma cells.
3.6. uPAR Promotes In Vitro Invasion of Human Chon-
drosarcoma Cells. Cell migration is a prerequisite for cancer
invasion. Therefore, we performed in vitro matrigel inva-
sion assays [33]t oq u a n t i f y ,t h er e l a t i v ei n v a s i v ep o t e n t i a l
of chondrosarcoma cells. In these assays, 10% FBS was
employed as a source of chemoattractants and the basal cell
invasion, assessed in theabsence ofany chemoattractant, was
taken as 100%. We employed the uPAR expressing human
ﬁbrosarcoma HT1080 cells as an internal control. AccordingSarcoma 7
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Figure 4: Chondrosarcoma cells express uPAR and release its soluble forms in the medium. Chondrosarcoma cells were ﬁxed with 2.5%
formaldeyde (a) or ﬁxed with 2.5% formaldeyde and permeabilized with 0.2% Triton X-100 (b) for 10min at 4◦C, incubated overnight at
4◦Cw i t h2μg/mL R4 anti-uPAR mAb and then exposed to Alexa 488-conjugated F(ab’)2 fragmentof rabbit anti-mouse IgG (green). Nuclei
were stained blue with DAPI. Original magniﬁcation: x1000. (c) Flow cytometry analysis of uPAR on chondrosarcoma and HT1080 cell
surfaces. HT1080 and chondrosarcoma cells were harvested, incubated with normal rat serum added to PBS (green and blue curves, resp.)
or 2μg/mL R4 anti-uPAR mAb (black and red curves, resp.), stained with Alexa 488-conjugated F(ab’)2 rabbit anti-mouse IgG and analyed
byFACS.(d)Chondrosarcomacells releasesolubleformsofuPARinthemedium.LB6,LB6/hSuPAR,orchondrosarcomacellsweregrownto
80% conﬂuence. Growth medium was removed, cells were extensively washed with PBS and then incubated in serum-free medium for 18h.
The medium was recovered, cleared by centrifugation, and analysed for SuPAR content by ELISA. Antigen concentrations were expressed as
ngSuPAR per μg proteins. Columns,meanoftwo independent experiments; bars, ±SD, ∗P<. 001 againstthe control (conditioned medium
of LB6 wild-type cells). (e) 500μL conditioned media of LB6, LB6/hSuPAR or chondrosarcoma cells were immunoprecipitated with 100μL
rabbit 399 anti-uPAR Ab conjugated to sepharose beads for 18h at 4◦C. The eluted proteins were separated by a 12.5% SDS-PAGE and
analysedby Western blot using R4 anti-uPAR mAb. 1μg puriﬁed SuPAR or 10μL 399 anti-uPAR conjugated to sepharose beads (none) were
loaded as a control. Arrows indicate the full-length SuPAR and the DIIDIII fragment of SuPAR.
to their previously reported highly invasive capability [20],
HT1080 cells exhibited a strong ability to cross matrigel (597
± 30% of the basal level). Chondrosarcoma cells exhibited a
very high ability to invade matrigel as compared to HT1080
cells, reaching 721 ± 91% of the basal level (Figure 5(a)).
Interestingly, cell exposure to blocking 399 anti-uPAR or
anti-uPAR84–95 Abs strongly reduced cell invasion ability of
bothHT1080andchondrosarcoma cells.Tofurther elucidate
the role of uPAR in promoting cell invasiveness, a subset
of experiments were performed in the presence of RERF
peptide which we have previously reported to speciﬁcally
inhibituPAR88–92-dependentsignalling without aﬀectingcell
proliferation [20]. We found that cell exposure to 10nM
RERF strongly reduced the ability of both HT1080 and
chondrosarcoma cells to cross matrigel whereas the ERFR
control peptide failed to exert any inhibitory eﬀect. These
ﬁndings strongly support the role of uPAR in promoting
cell invasion. To assess whether also soluble forms of uPAR
may be involved in cell invasion capability, experiments
were performed using conditioned medium of LB6/hSuPAR
cells as a source of intact and DIIDIII uPAR fragment, or
conditioned medium of LB6 cells as a negative control. We
found that both HT1080 and chondrosarcoma cells respond
to LB6/hSuPAR conditioned medium, the eﬀect being pre-
vented by 399 anti-uPAR as well as by anti-uPAR84–95 Abs
(Figure 5(b)).8 Sarcoma
Table 3: SuPAR-dependent migrationof chondrosarcoma cells.
Supplements Eﬀector
Cell migration (%)
HT1080 cells Chondrosarcoma cells
DMEM
DMEM 100 100
CM LB6 110 ± 5 112 ± 8
CM LB6/SuPAR 401 ± 12∗∗ 363 ± 16∗∗
10nM DI1–87 115 ± 6 105 ± 8
10nM DII88–183 265 ± 9∗∗ 215 ± 5∗∗
10nM DIII184–284 98 ± 9∗ 100 ± 6
10nM DIIDIII88–284 259 ± 11∗∗ 221 ± 13∗
10nM DIDIIDIII1–284 270 ± 15∗ 240 ± 10∗∗
NRS
DMEM 100 ± 3 100 ± 2
CM LB6/SuPAR 398 ± 9∗∗ 351 ± 6∗∗
10nM DII88–183 271 ± 5∗∗ 225 ± 11∗∗
10nM DIIDIII88–284 262 ± 9∗∗ 200 ± 8∗∗
10nM DIDIIDIII1–284 250 ± 9∗ 236 ± 13∗
399 Anti-uPAR Ab
DMEM 100 ± 7 100 ± 5
CM LB6/SuPAR 145 ± 12 133 ± 10
10nM DII88–183 115 ± 6 124 ± 9
10nM DIIDIII88–284 106 ± 11 99 ± 13
10nM DIDIIDIII1–284 110 ± 17 102 ± 14
Anti-uPAR84–95 Ab
DMEM 100 ± 6 100 ± 5
CM LB6/SuPAR 124 ± 9 130 ± 6
10nM DII88–183 104 ± 13 101 ± 7
10nM DIIDIII88–284 102 ± 9 119 ± 15
10nM DIDIIDIII1–284 107 ± 11 110 ± 13
Cells incubated with diluents (DMEM) or 5μg/mL the indicated antibody for 1h at 37◦C were seeded in Boyden chambers for cell migration assays as
describedin theMaterialand Method section, inthe presence or absenceof the indicatedeﬀectors. Conditioned medium (CM) of LB6/hSuPAR cells was used
as a source of SuPAR. For quantitativeanalysisofcell migration,the basalvalue (DMEM) was takenas 100%and all values were reported relative to that.D ata
are the means ± SD of two independent experiments, performed in duplicate. Statisticalsigniﬁcance with P values was calculated against the control DMEM.
∗Statisticalsigniﬁcance with P<. 05. ∗∗Statisticalsigniﬁcance with P<. 001.
4.Conclusions
uPAR plays a key role in pathological processes sustained
by an altered cell migration [11]. High levels of uPAR
and SuPAR in tissue and serum of patients with sarcoma,
including chondrosarcoma, correlate with a poor prognosis
[25]. We generated a primary cell culture derived from
a uPAR overexpressing chondrosarcoma tissue. We found
that chondrosarcoma-like primary culture cells express high
level of uPAR on plasma cell membranes and release a
large amount of intact SuPAR as well as DIIDIII uPAR
fragment in the medium. Our ﬁndings revealed that,
in vitro, SuPAR: (i) elicits chondrosarcoma cell migra-
tion through its uPAR88–92 sequence and (ii) promotes
chondrosarcoma cell invasion, the eﬀect being reduced
to the basal level by anti-uPAR blocking antibody. Taken
together, our ﬁndings raises the possibility that soluble
uPAR released by chondrosarcoma cells in the extracel-
lular matrix may generate a chemotactic gradient which,
in turn, stimulates tumor cells to migrate and invade
the surrounding tissues. There are few studies investigating
the clinical impact of uPAR expression and its correlation
to prognosis in chondrosarcoma [25]. Our ﬁndings sug-
gest that the determination of plasmatic SuPAR content
in patients with chondrosarcoma could be helpful for a
prognostic evaluation. Furthermore, there are currently no
universally eﬀective therapies for unresectable or metasta-
sized chondrosarcomas [1]. It can be envisaged that the
inhibition of uPAR activity could be a promising strategy
to prevent chondrosarcoma invasion and metastasis. We
found that, in vitro, the chondrosarcoma cell invasion
ability may be abrogated by RERF peptide which speciﬁcally
inhibits the uPAR88–92-dependent signalling by preventing
its interaction with the G-protein coupled formyl-peptide
receptor [20]. In conclusion, our data indicate that uPAR is
required for the cell migration and invasion machinery of
chondrosarcoma cells and suggest that RERF peptide may
be regarded as a prototype to generate new therapeutic
agents for the treatment of unresectable or metastasized
chondrosarcoma.Sarcoma 9
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Figure 5: uPAR-dependent matrigel invasion of chondrosarcoma.
Cells human ﬁbrosarcoma HT1080 and chondrosarcoma cells
were subjected to cell invasion assays. Cells were preincubated
with DMEM (none), 2μg/mL indicated anti-uPAR antibodies,
10nM RERF peptide or 10nM ERFR peptide, plated in Boy-
den chambers and allowed to cross matrigel-coated ﬁlters for
18h at 37◦C in humidiﬁed air with 5% CO2. 10% FBS (a),
LB6, or LB6/hSuPAR conditioned media (b) were employed as
chemoattractants. In all cases, data are reported as a percentage
of invading cells in the absence of chemoattractant, considered
as 100% (DMEM), and represent the average of two experi-
ments, performed in duplicate. Columns, mean of two indepen-
dent experiments; bars, ±SD, ∗P<. 001 against the control
(DMEM).
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